SPECIAL FEATURES

Highlights of This Issue 7435

CCR Translations

7437 Jumping the Barrier: Modeling Drug Penetration across the Blood–Brain Barrier
Cody J. Peer, Cindy H. Chau, and William D. Figg
See related article, p. 7454

Statistics in CCR

7440 Dose Transition Pathways: The Missing Link Between Complex Dose-Finding Designs and Simple Decision-Making
Christina Yap, Lucinda J. Billingham, Ying Kuen Cheung, Charlie Craddock, and John O’Quigley

CCR Drug Updates

7448 FDA Approval Summary: Trabectedin for Unresectable or Metastatic Liposarcoma or Leiomyosarcoma Following an Anthracycline-Containing Regimen
Amy Barone, Dow-Chung Chi, Marc R. Theoret, Huanxy Chen, Kun He, Dubravka Kufrin, Whitney S. Helms, Sriram Subramaniam, Hong Zhao, Anuja Patel, Kirsten B. Goldberg, and Richard Pazdur

CANCER THERAPY: CLINICAL

7454 Quantitative and Mechanistic Understanding of AZD1775 Penetration across Human Blood–Brain Barrier in Glioblastoma Patients: IVIVE–PBPK Modeling Approach
Jing Li, Jannet Wu, Xun Bao, Notissa Honex, Youming Xie, Seongho Kim, Alex Sparreboom, and Nader Sanai
See related commentary, p. 7337

7457 A Phase I, Dose Escalation Study of Oral ASP8273 in Patients with Non–small Cell Lung Cancers with Epidermal Growth Factor Receptor Mutations

7474 Immune Activation in Early-Stage Non–Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab
John S. Yi, Neal Ready, Patrick Healy, Chelsee Dumbauld, Robyn Osborne, Mark Berry, Debra Shoemaker, Jeffrey Clarke, Jeffrey Crawford, Betty Tong, David Harpole, Thomas A. D’Amico, Frances McSherry, Frank Dunphy, Shannon J. McCall, Jared D. Christensen, Xiaofei Wang, and Kent I. Weinhold

7483 A Randomized Phase II Trial of Adjuvant Galinpepimut-S, WT-1 Analogue Peptide Vaccine, After Multimodality Therapy for Patients with Malignant Pleural Mesothelioma
Marjorie G. Zauderer, Anne S. Tsao, Tao Dao, Katherine Panageas, W. Victoria Lai, Andreas Rimmer, Valerie W. Rusch, Prasad S. Adusumilli, Michelle S. Ginsberg, Daniel Gomez, David Rice, Reza Mehran, David A. Scheinberg, and Lee M. Krug

7490 A First-in-Human Phase I Study of the Anticancer Stem Cell Agent Ipafircept (OMP-54F28), a Decoy Receptor for Wnt Ligands, in Patients with Advanced Solid Tumors
Antonio Jimeno, Michael Gordon, Rashmi Chugh, Wells Messersmith, David Mendelson, Jakob Dupont, Robert Stagg, Ann M. Kapoun, Lu Xu, Shalai Kuttamsingh, Rainer K. Brachmann, and David C. Smith

7498 Monocytes and Granulocytes Reduce CD38 Expression Levels on Myeloma Cells in Patients Treated with Daratumunab

PERSONALIZED MEDICINE AND IMAGING

7512 Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts
Table of Contents

7521 Homologous Recombination Deficiency and Platinum-Based Therapy Outcomes in Advanced Breast Cancer
Eric Y. Zhao, Yaoqing Shen, Erin Pleasance, Katayoon Kasaiian, Sreeja Leelakumari, Martin Jones, Pinaki Bose, Carolyn Ch'ng, Caralyn Reisle, Peter Eirew, Richard Cosbett, Karen L. Mungall, Nina Thiessen, Yussanne Ma, Jacqueline E. Schein, Andrew J. Mungall, Yongjun Zhao, Richard A. Moore, Wendie Den Brok, Sheridan Wilson, Diego Villa, Tamara Shenkier, Caroline Lohrisch, Stephen Chia, Stephen Yap, Karen Gelmon, Howard Lim, Daniel Renouf, Sophie Sun, Kasminathan A. Schrader, Sean Young, Ian Bosdet, Aly Karsan, Janessa Laskin, Marco A. Marra, and Steven J.M. Jones

7531 In Vivo Detection of HSP90 Identifies Breast Cancers with Aggressive Behavior
Takuya Osada, Kensuke Kaneko, William R. Gwin, Michael A. Morse, Amy Hobeika, Brian W. Pogue, Zachary C. Hartman, Philip F. Hughes, Timothy Haystead, and H. Kim Lyerly

7543 Pharmacogenetic Analysis of the UK MRC (Medical Research Council) MAGIC Trial: Association of Polymorphisms with Toxicity and Survival in Patients Treated with Perioperative Epirubicin, Cisplatin, and 5-fluorouracil (ECF) Chemotherapy
Elizabeth Smyth, Shendi Zhang, David Cunningham, Andrew Womerspoon, Richie Soong, Clare Peckitt, Nicola Valeri, Matteo Fassan, Massimo Rugge, Alicia Okines, William Allum, Sally Stenning, Matthew Nankivell, Ruth Langley, and Patrick Tan

7550 Common TDP1 Polymorphisms in Relation to Survival among Small Cell Lung Cancer Patients: A Multicenter Study from the International Lung Cancer Consortium
Pawadee Lohavanichbutr, Lori C. Sakoda, Christopher I. Amos, Susanne M. Arnold, David C. Christiani, Michael P.A. Davies, John K. Field, Eric B. Haura, Rayeun J. Hung, Takashi Kohno, Maria Teresa Landi, Geoffrey Liu, Yi Liu, Michael W. Marcus, Grainne M. O’Kane, Matthew B. Schabath, Kouya Shiraishi, Stacey A. Slone, Adonina Tard /C19 on, Ping Yang, Kazushi Yoshida, Ruyang Zhang, Xuchen Zong, Gary E. Goodman, Noel S. Weiss, and Chu Chen

7558 CANCER THERAPY: PRECLINICAL

7558 Modulation of Navitoclax Sensitivity by Dihydroartemisinin-Mediated MCL-1 Repression in BCR-ABL ÷ B-Lineage Acute Lymphoblastic Leukemia
Amit Budhraj, Meghan E. Tunis, Michelle L. Churchman, Anisha Kothari, Xue Yang, Haiyan Xu, Ewa Kaminska, John C. Panetta, David Finkelstein, Charles G. Mullighan, and Joseph T. Opferman

7569 CAR T Therapy Targeting ICAM-1 Eliminates Advanced Human Thyroid Tumors
Irene M. Min, Enda Shevliv, Yogindra Vedvayas, Marjan Zaman, Brian Wyrwas, Theresa Scognamiglio, Maureen D. Moore, Weibin Wang, Susan Park, Spencer Park, Suraj Panjwani, Katherine D. Gray, Andrew B. Tassler, Rasa Zamegar, Thomas J. Fahey III, and Moonsoo M. Jin

7574 Inhibiting PI3Kδ with AZD8186 Regulates Key Metabolic Pathways in Pten-Null Tumors

7596 Mutational Analysis of Gene Fusions Predicts Novel MHC Class I–Restricted T-Cell Epitopes and Immune Signatures in a Subset of Prostate Cancer

7608 Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor–Positive Breast Cancer Models with a Distinct Mechanism of Action
Ziyang Yu, Suqin He, Dannie Wang, Hitishi K. Patel, Chris P. Miller, Jeffrey L. Brown, Gary Hattersley, and Jamal C. Saeh
Table of Contents

BIOLOGY OF HUMAN TUMORS

7621 A Complex Network of Tumor Microenvironment in Human High-Grade Serous Ovarian Cancer

7633 The Driver Mutational Landscape of Ovarian Squamous Cell Carcinomas Arising in Mature Cystic Teratoma

7641 Head and Neck Squamous Cell Carcinomas Are Characterized by a Stable Immune Signature Within the Primary Tumor Over Time and Space
Oliver Wood, James Clarke, Jeongmin Woo, Adal H. Mirza, Christopher H. Woelk, Gareth J. Thomas, Pandurangan Vijayanand, Emma King, and Christian H. Ottensmeier

7650 Transmembrane and Coiled-Coil Domain 1 Impairs the AKT Signaling Pathway in Urinary Bladder Urothelial Carcinoma: A Characterization of a Tumor Suppressor
Chien-Feng Li, Wen-Ren Wu, Ti-Chun Chan, Yu-Hui Wang, Lih-Ren Chen, Wen-Jeng Wu, Bi-Wen Yeh, Shih-Shin Liang, and Yow-Ling Shiue

7664 Acknowledgment to Reviewers

ABOUT THE COVER
The cover shows a section of a HBCx-22 AR/ER+ breast cancer patient-derived xenograft. Immunohistochemical staining shows AR expression in both the cytoplasm and the nuclei. For details, see the article by Yu and colleagues on page 7608 of this issue.
Clinical Cancer Research

23 (24)


Updated version
Access the most recent version of this article at:
http://clincancerres.aacrjournals.org/content/23/24

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, use this link http://clincancerres.aacrjournals.org/content/23/24.
Click on "Request Permissions" which will take you to the Copyright Clearance Center's (CCC) Rightslink site.